A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)

Trial Profile

A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)

Suspended
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rosomidnar (Primary)
  • Indications Chronic lymphocytic leukaemia; Leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms Brighton
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
    • 06 Jun 2016 Status changed from recruiting to suspended, according to a ProNAi Therapeutics media release.
    • 06 Jun 2016 According to a ProNAi Therapeutics media release, the company decided to close this study to further enrollment of new subjects based on the interim assessments.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top